Judge Rebecca A. Sanders, chair of the Workers Compensation Appeals Board of the Kansas Department of Labor, Topeka, is the ...
Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently ...
Camila Colin, 17, attended the groundbreaking ceremony for Keaton’s House: Paul Paletta Children’s Hospice in Dundas, Ont., ...
“Marketresearch.biz reports that the Ataxia market was valued at USD 11,558.3 million in 2023. It is expected to reach USD 20,778.5 million by 2033, with a CAGR of 6.20% during the forecast period ...
Wheelchair accessible vehicles supplier, Allied Mobility, has announced its support for Geraint Williams, an inspirational ...
Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from ...
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced this week that the U.S. Food and Drug Administration ...
Larimar will continue the open label extension study in Friedreich’s ataxia with results expected in Q4 this year.
Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback